If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Tauvid ™ (flortaucipir F18 injection)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How does Tauvid™ (flortaucipir F 18) work?
Tauvid (flortaucipir F 18) selectively binds to aggregated tau protein, with no significant binding to beta-amyloid, α-synuclein, or non-Alzheimer’s disease tau conformations.
Flortaucipir F 18 Mechanism of Action
Flortaucipir F 18 binds to aggregated tau protein. In the brains of patients with Alzheimer's disease (AD), tau aggregates combine to form neurofibrillary tangles, one of two components required for the neuropathological diagnosis of AD.1
In vitro, flortaucipir F 18
- binds to paired helical filament (PHF) tau purified from brain homogenates of donors with AD, and
- has a dissociation constant (Kd) from PHFs of 0.57 nM.1
In vivo, flortaucipir F 18 is differentially retained in neocortical areas that contain aggregated tau.1
Enclosed Prescribing Information
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Tauvid [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
2Xia C-F, Arteaga J, Chen G, et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9(6):666-676. https://doi.org/10.1016/j.jalz.2012.11.008
3Marquié M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787-800. http://dx.doi.org/10.1002/ana.24517
Date of Last Review: January 12, 2022